Sailong Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN

P/E

181.10

P/S

5.56

EPS

0.05

Div Yield, %

0.32%

Shrs. gr., 5y

-0.01%

Rev. gr., 5y

-6.57%

Revenues

311m

+17.58%

Net income

10m

CFO

36m

+152.80%

Dividend

Jun 28, 20240.02 CNY/sh

Earnings

May 16, 2025

Profile

Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, gaicycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, and pantoprazole sodium products. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding medicine, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co., Ltd. in September 2021. Sailong Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Zhuhai, China.

URL

http://www.sailong.cn

IPO date

Sep 12, 2017

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	310,627 17.58%	264,193 6.93%	247,079 104.73%
Cost of revenue	273,248	258,858	232,056
Unusual Expense (Income)
NOPBT	37,379	5,334	15,022
NOPBT Margin	12.03%	2.02%	6.08%
Operating Taxes	12,823	7,642	9,572
Tax Rate	34.30%	143.25%	63.72%
NOPAT	24,557	(2,307)	5,450
Net income	9,534
Dividends	(5,579)	(8,695)	(7,891)
Dividend yield	0.23%	0.41%	0.43%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	90,048	129,935	129,871
Long-term debt	25,156	13,679	43,444
Deferred revenue	2,842	3,084	3,326
Other long-term liabilities	13,232
Net debt	(43,915)	(8,459)	(3,074)
Cash flow
Cash from operating activities	35,707	14,125	35,461
CAPEX	(30,579)
Cash from investing activities	(19,325)
Cash from financing activities			42,498
FCF	42,948	32,595	55,888
Balance
Cash	89,262	72,270	113,309
Long term investments	69,856	79,803	63,080
Excess cash	143,587	138,864	164,036
Stockholders' equity	265,422	237,879	275,192
Invested Capital	523,535	523,890	570,586
ROIC	4.69%		0.92%
ROCE	5.52%	0.79%	2.03%
EV
Common stock shares outstanding	175,898	176,000	176,000
Price	13.97 14.98%	12.15 16.27%	10.45 11.65%
Market cap	2,457,298 14.91%	2,138,400 16.27%	1,839,200 11.65%
EV	2,431,393	2,129,941	1,836,126
EBITDA	70,511	39,396	47,819
EV/EBITDA	34.48	54.06	38.40
Interest	6,907	8,085	6,597
Interest/NOPBT	18.48%	151.55%	43.91%